Zacks Research Issues Pessimistic Forecast for PRE Earnings

Key Points

• Zacks Research cut its FY2027 EPS forecast for Prenetics Global to $1.49 from $1.56, while the current full-year consensus estimate remains a loss of $1.28 per share.
• Prenetics reported a quarterly loss of $0.53 per share, beating expectations for a $0.64 loss, but revenue of $46.49 million came in below the $49.02 million consensus. The company posted a negative 47.43% net margin and 19.46% return on equity.
• Shares opened at $18.76 after declining 3.3%; analyst sentiment is mixed, with four Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $34.25.

Prenetics Global Limited (NASDAQ:PRE - Free Report) - Equities research analysts at Zacks Research dropped their FY2027 earnings per share estimates for shares of Prenetics Global in a research note issued on Tuesday, August 18th. Zacks Research analyst B. Sorensen now anticipates that the company will earn $1.49 per share for the year, down from their previous forecast of $1.56. The consensus estimate for Prenetics Global's current full-year earnings is ($1.28) per share.

Prenetics Global (NASDAQ:PRE - Get Free Report) last posted its quarterly earnings data on Tuesday, August 18th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.11. Prenetics Global had a negative return on equity of 19.46% and a negative net margin of 47.43%.The company had revenue of $46.49 million during the quarter, compared to analyst estimates of $49.02 million.

Other equities analysts have also issued research reports about the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Prenetics Global in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Prenetics Global from a "hold" rating to a "sell" rating in a research report on Saturday, July 25th. Finally, Benchmark raised their price objective on shares of Prenetics Global from $30.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, July 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $34.25.

Prenetics Global Trading Down 3.3%

NASDAQ PRE opened at $18.76 on Thursday. Prenetics Global has a 12 month low of $7.18 and a 12 month high of $23.63. The stock's fifty day moving average price is $19.13 and its 200-day moving average price is $18.88. The stock has a market cap of $316.48 million, a P/E ratio of -4.51 and a beta of 0.26.

Institutional Trading of Prenetics Global

A number of institutional investors and hedge funds have recently modified their holdings of the business. 683 Capital Management LLC bought a new position in shares of Prenetics Global during the fourth quarter valued at $1,181,000. Manatuck Hill Partners LLC bought a new stake in Prenetics Global in the 4th quarter worth about $170,000. UBS Group AG increased its holdings in Prenetics Global by 581.9% in the 3rd quarter. UBS Group AG now owns 46,561 shares of the company's stock worth $619,000 after buying an additional 39,733 shares in the last quarter. Marshall Wace LLP purchased a new position in Prenetics Global in the 4th quarter worth about $788,000. Finally, Jane Street Group LLC purchased a new position in Prenetics Global in the 4th quarter worth about $1,302,000. Institutional investors own 25.01% of the company's stock.

About Prenetics Global

Prenetics Global NASDAQ: PRE is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company's core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source